Suppr超能文献

小儿拉氧头孢给药方案调整与药学监护

Latamoxef dosing regimen adjustments and pharmaceutical care in pediatrics.

作者信息

Zhang Ailin, Zuo Meiling, Sun Yuxuan, Chen Jingtao, Zhu Liqin, Liu Wei

机构信息

First Central Clinical College, Tianjin Medical University, Tianjin, China.

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Diseases, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.

出版信息

Front Pediatr. 2024 Feb 1;12:1302087. doi: 10.3389/fped.2024.1302087. eCollection 2024.

Abstract

Latamoxef is a semi-synthetic, broad-spectrum oxacephem antibiotic used primarily to treat infectious diseases, but the adverse drug reactions, such as the risk of fatal bleeding, once caused physicians to use it less frequently. However, with the rise of antibiotic-resistant bacterial strains, latamoxef is being used again to treat infectious diseases, especially in pediatrics. The pharmacokinetic parameters of latamoxef are highly variable, given the changes in body composition, organ maturation, and development that occurs in pediatrics. Therefore, an appropriate dosing regimen is essential. Latamoxef dosing optimization in pediatrics should adequately account for current body weight, postnatal age, postmenstrual age, and different minimum inhibitory concentration (MIC) values. In addition, attention should also be paid to some of the adverse reactions associated with latamoxef, such as coagulation disorders and bleeding risks, disulfiram-like reactions, as well as hypersensitivity and anaphylactic shock. This review summarizes the dosing regimens and some key points of pharmaceutical care for latamoxef in pediatrics in order to provide a better reference for its application in clinical practice.

摘要

拉氧头孢是一种半合成的广谱氧头孢烯类抗生素,主要用于治疗感染性疾病,但曾因诸如致命性出血风险等药物不良反应,导致医生较少使用。然而,随着耐抗生素菌株的增多,拉氧头孢再次被用于治疗感染性疾病,尤其是在儿科。鉴于儿科患者身体组成、器官成熟度和发育情况的变化,拉氧头孢的药代动力学参数差异很大。因此,制定合适的给药方案至关重要。儿科拉氧头孢给药方案的优化应充分考虑当前体重、出生后年龄、月经后年龄以及不同的最低抑菌浓度(MIC)值。此外,还应关注与拉氧头孢相关的一些不良反应,如凝血障碍和出血风险、双硫仑样反应以及过敏和过敏性休克。本综述总结了儿科拉氧头孢的给药方案及药学监护要点,以便为其临床应用提供更好的参考。

相似文献

1
Latamoxef dosing regimen adjustments and pharmaceutical care in pediatrics.
Front Pediatr. 2024 Feb 1;12:1302087. doi: 10.3389/fped.2024.1302087. eCollection 2024.
2
Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
Int J Antimicrob Agents. 2019 Mar;53(3):347-351. doi: 10.1016/j.ijantimicag.2018.11.017. Epub 2018 Nov 22.
3
Latamoxef for Neonates With Early-Onset Neonatal Sepsis: A Study Protocol for a Randomized Controlled Trial.
Front Pharmacol. 2021 Jun 9;12:635517. doi: 10.3389/fphar.2021.635517. eCollection 2021.
4
Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.
Pharmaceutics. 2022 May 11;14(5):1033. doi: 10.3390/pharmaceutics14051033.
5
Latamoxef-induced coagulation disorders: Incidence and risk factors.
J Clin Pharm Ther. 2021 Oct;46(5):1382-1386. doi: 10.1111/jcpt.13435. Epub 2021 Jun 10.
6
Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
Eur J Pediatr. 2023 Sep;182(9):4143-4152. doi: 10.1007/s00431-023-05103-z. Epub 2023 Jul 12.
7
Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
J Pharm Sci. 2015 Sep;104(9):3194-8. doi: 10.1002/jps.24432. Epub 2015 Mar 26.
9
Empirical treatment of febrile, neutropenic patients with tobramycin and latamoxef.
J Hosp Infect. 1987 May;9(3):278-84. doi: 10.1016/0195-6701(87)90125-3.
10
Comparison of flomoxef with latamoxef in the treatment of sepsis and/or Gram-negative bacteremia in adult patients.
Int J Antimicrob Agents. 1996 May;7(1):69-74. doi: 10.1016/0924-8579(96)00013-1.

本文引用的文献

1
Latamoxef-induced severe thrombocytopenia during the treatment of pulmonary infection: A case report.
World J Clin Cases. 2022 Aug 6;10(22):7906-7912. doi: 10.12998/wjcc.v10.i22.7906.
2
Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.
Pharmaceutics. 2022 May 11;14(5):1033. doi: 10.3390/pharmaceutics14051033.
3
Latamoxef-induced coagulation disorders: Incidence and risk factors.
J Clin Pharm Ther. 2021 Oct;46(5):1382-1386. doi: 10.1111/jcpt.13435. Epub 2021 Jun 10.
4
Latamoxef induced a severe coagulation disorder in older patients in China: Two case reports.
J Clin Pharm Ther. 2021 Feb;46(1):227-229. doi: 10.1111/jcpt.13266. Epub 2020 Sep 19.
5
The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis.
Int J Environ Res Public Health. 2019 Oct 16;16(20):3937. doi: 10.3390/ijerph16203937.
6
Disulfiram-like Reaction With Metronidazole: An Unsuspected Culprit.
J Pediatr Pharmacol Ther. 2019 Sep-Oct;24(5):445-449. doi: 10.5863/1551-6776-24.5.445.
7
Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
Int J Antimicrob Agents. 2019 Mar;53(3):347-351. doi: 10.1016/j.ijantimicag.2018.11.017. Epub 2018 Nov 22.
8
Disulfiram-like Reaction Involving Ceftriaxone in a Pediatric Patient.
J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):168-171. doi: 10.5863/1551-6776-23.2.168.
9
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.
Curr Opin Pharmacol. 2017 Oct;36:107-113. doi: 10.1016/j.coph.2017.09.009. Epub 2017 Nov 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验